Natera (NASDAQ:NTRA) Stock: Insider John Fesko Sells 781 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 781 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $406.00, for a total value of $317,086.00. Following the completion of the sale, the insider owned 196,476 shares of the company’s stock, valued at $79,769,256. The trade was a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $382,853.32.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The stock was sold at an average price of $267.99, for a total value of $79,057.05.

Natera Trading Down 5.0%

NASDAQ:NTRA opened at $414.30 on Friday. The company has a fifty day moving average of $377.06 and a 200-day moving average of $266.44. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.74) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Institutional Trading of Natera

Several hedge funds have recently added to or reduced their stakes in the stock. Trust Co. of Vermont bought a new position in shares of Natera during the 2nd quarter valued at approximately $26,000. Elevation Wealth Partners LLC bought a new stake in shares of Natera in the 2nd quarter worth approximately $30,000. Continuum Advisory LLC bought a new stake in shares of Natera in the 2nd quarter worth approximately $33,000. International Assets Investment Management LLC raised its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the period. Finally, Rakuten Securities Inc. purchased a new position in Natera in the second quarter valued at approximately $35,000. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Piper Sandler upped their target price on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Roth Capital assumed coverage on shares of Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price objective for the company. Canaccord Genuity Group lifted their target price on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company boosted their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $394.31.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.